Puma Biotechnology (PBYI) Financials

Puma Biotechnology logo
$6.98 -0.37 (-4.97%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Puma Biotechnology

Annual Income Statements for Puma Biotechnology

This table shows Puma Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Consolidated Net Income / (Loss)
-239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Net Income / (Loss) Continuing Operations
-239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Total Pre-Tax Income
-239 -276 -292 -114 -76 -60 -29 0.46 23 24 36
Total Operating Income
-240 -277 -292 -95 -39 -30 1.29 24 33 31 37
Total Gross Profit
0.00 0.00 22 216 235 186 189 173 173 166 170
Total Revenue
0.00 0.00 28 251 272 225 253 228 236 230 228
Operating Revenue
- - 28 251 272 225 253 228 236 230 228
Total Cost of Revenue
0.00 0.00 5.57 35 37 39 64 55 63 64 58
Operating Cost of Revenue
- - 5.57 35 37 39 64 55 63 64 58
Total Operating Expenses
240 277 315 311 274 216 188 149 140 135 133
Selling, General & Admin Expense
32 54 107 146 142 118 116 90 90 80 71
Research & Development Expense
208 223 208 165 133 98 72 59 50 55 62
Total Other Income / (Expense), net
1.00 0.59 0.44 -19 -36 -29 -30 -23 -9.97 -6.87 -1.52
Interest Expense
- - 0.72 11 23 14 21 12 13 12 6.62
Interest & Investment Income
0.97 0.96 1.26 1.80 2.85 0.49 0.16 0.81 2.61 4.72 4.08
Other Income / (Expense), net
0.03 -0.37 -0.10 -9.71 -16 -16 -9.30 -12 0.76 0.86 1.03
Income Tax Expense
- - - 0.02 0.05 0.21 0.32 0.46 1.08 -6.18 4.67
Basic Earnings per Share
($7.45) ($8.29) ($7.85) ($2.99) ($75,595.00) ($1.52) ($0.72) $0.00 $0.46 $0.62 $0.62
Weighted Average Basic Shares Outstanding
32.13M 33.30M 37.17M 37.94M 38.77M 39.58M 40.64M 44.67M 47.13M 48.65M 50.01M
Diluted Earnings per Share
($7.45) ($8.29) ($7.85) ($2.99) - ($1.52) ($0.72) $0.00 $0.45 $0.62 $0.61
Weighted Average Diluted Shares Outstanding
32.13M 33.30M 37.17M 37.94M 38.77M 39.58M 40.64M 44.93M 47.55M 49.10M 50.65M
Weighted Average Basic & Diluted Shares Outstanding
32.13M 33.30M 37.17M 37.94M 38.77M 39.58M 40.64M 46.64M 48.21M 49.61M 50.88M

Quarterly Income Statements for Puma Biotechnology

This table shows Puma Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75 8.19 5.96
Consolidated Net Income / (Loss)
-4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75 8.19 5.96
Net Income / (Loss) Continuing Operations
-4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75 8.19 5.96
Total Pre-Tax Income
-4.60 -4.15 21 12 3.27 6.17 9.24 17 -3.43 8.25 6.17
Total Operating Income
-2.30 -2.18 22 13 3.98 6.64 9.57 17 -3.83 7.59 5.27
Total Gross Profit
33 36 51 45 35 40 42 52 34 44 40
Total Revenue
44 47 81 59 46 52 54 75 45 57 55
Operating Revenue
44 47 81 59 46 52 54 75 45 57 55
Total Cost of Revenue
11 11 29 14 11 12 12 23 10 12 15
Operating Cost of Revenue
11 11 29 14 11 12 12 23 10 12 15
Total Operating Expenses
35 39 29 32 31 33 33 35 38 36 35
Selling, General & Admin Expense
22 25 17 17 18 18 17 18 18 18 16
Research & Development Expense
14 14 13 15 14 15 16 17 20 19 18
Total Other Income / (Expense), net
-2.30 -1.97 -1.47 -1.13 -0.72 -0.47 -0.33 0.00 0.40 0.66 0.90
Interest Expense
3.36 3.37 3.10 2.62 2.18 1.84 1.49 1.12 0.73 0.18 0.00
Interest & Investment Income
0.97 1.24 1.28 1.23 1.10 0.96 1.04 0.98 1.00 0.83 0.88
Other Income / (Expense), net
0.09 0.16 0.35 0.27 0.36 0.41 0.12 0.14 0.13 0.01 0.02
Income Tax Expense
0.22 0.38 0.29 -7.07 0.29 0.31 0.40 3.67 0.33 0.06 0.22
Basic Earnings per Share
($0.10) ($0.09) $0.41 $0.40 $0.06 $0.12 $0.18 $0.26 ($0.07) $0.16 $0.12
Weighted Average Basic Shares Outstanding
48.19M 48.29M 49.01M 48.65M 49.60M 49.70M 50.34M 50.01M 50.85M 50.94M 51.60M
Diluted Earnings per Share
($0.10) ($0.09) $0.41 $0.40 $0.06 $0.12 $0.17 $0.26 ($0.07) $0.16 $0.11
Weighted Average Diluted Shares Outstanding
48.19M 48.29M 49.17M 49.10M 49.91M 50.14M 50.93M 50.65M 50.85M 52.60M 53.12M
Weighted Average Basic & Diluted Shares Outstanding
48.24M 49.05M 49.09M 49.61M 49.64M 50.37M 50.39M 50.88M 50.90M 51.62M 51.70M

Annual Cash Flow Statements for Puma Biotechnology

This table details how cash moves in and out of Puma Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-6.97 163 -113 27 -40 24 -22 3.50 7.88 -15 -40
Net Cash From Operating Activities
-154 -142 -172 -24 22 0.77 21 -16 27 39 42
Net Cash From Continuing Operating Activities
-154 -142 -172 -24 22 -1.23 21 -16 27 39 42
Net Income / (Loss) Continuing Operations
-239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Consolidated Net Income / (Loss)
-239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Depreciation Expense
0.78 1.15 2.81 7.38 8.08 10 11 9.84 12 12 11
Non-Cash Adjustments To Reconcile Net Income
95 118 109 87 67 36 40 19 12 7.73 6.59
Changes in Operating Assets and Liabilities, net
-11 13 7.94 -5.14 23 13 -1.31 -44 -18 -11 -6.83
Net Cash From Investing Activities
-86 142 -15 -58 5.16 33 -11 7.10 -19 -20 -36
Net Cash From Continuing Investing Activities
-86 142 -15 -58 5.16 33 -11 7.10 -19 -20 -36
Purchase of Property, Plant & Equipment
-1.18 -7.28 -0.43 -0.61 -0.31 -0.05 0.00 0.00 -0.14 -0.06 -0.07
Acquisitions
- - -50 0.00 0.00 -10 0.00 -7.00 -13 0.00 0.00
Purchase of Investments
-215 -82 -80 -108 -127 -30 -38 -4.84 -24 -76 -108
Sale and/or Maturity of Investments
133 231 115 50 133 73 27 19 17 56 72
Net Cash From Financing Activities
233 162 75 108 -67 -9.93 -32 12 0.00 -34 -45
Net Cash From Continuing Financing Activities
233 162 75 108 -67 -9.93 -32 12 0.00 -34 -45
Repayment of Debt
- - -1.58 -4.20 -93 -8.44 -110 0.00 0.00 -34 -45
Issuance of Common Equity
233 162 27 7.65 1.35 0.07 0.00 13 0.00 0.15 0.13
Cash Interest Paid
- - 0.34 8.06 12 9.70 10 10 12 11 5.82
Cash Income Taxes Paid
- - - 0.02 0.05 0.21 0.32 0.38 0.74 1.22 1.52

Quarterly Cash Flow Statements for Puma Biotechnology

This table details how cash moves in and out of Puma Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-7.83 -9.60 0.11 1.96 -6.19 -8.37 -1.14 -24 6.56 -1.75 5.01
Net Cash From Operating Activities
11 1.03 11 16 3.61 14 9.69 14 15 1.62 15
Net Cash From Continuing Operating Activities
11 1.03 11 16 3.61 14 9.69 14 15 1.62 15
Net Income / (Loss) Continuing Operations
-4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75 8.19 5.96
Consolidated Net Income / (Loss)
-4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75 8.19 5.96
Depreciation Expense
2.90 2.91 2.88 2.84 2.80 2.76 2.72 2.66 2.58 2.52 2.45
Non-Cash Adjustments To Reconcile Net Income
2.49 1.88 2.01 1.35 2.24 1.27 1.46 1.62 1.90 1.95 2.02
Changes in Operating Assets and Liabilities, net
11 0.77 -14 -7.89 -4.40 4.20 -3.34 -3.29 15 -11 4.15
Net Cash From Investing Activities
-19 0.70 0.26 -2.32 1.53 -11 0.51 -27 2.47 7.97 -9.71
Net Cash From Continuing Investing Activities
-19 0.70 0.26 -2.32 1.53 -11 0.51 -27 2.47 7.97 -9.71
Purchase of Investments
-25 -20 -16 -15 -13 -22 -27 -47 -25 -22 -36
Sale and/or Maturity of Investments
5.89 21 16 13 14 11 27 20 27 30 26
Net Cash From Financing Activities
0.00 -11 -11 -11 -11 -11 -11 -11 -11 -11 0.15
Net Cash From Continuing Financing Activities
0.00 -11 -11 -11 -11 -11 -11 -11 -11 -11 0.15
Issuance of Common Equity
- - 0.15 - - - - - - - 0.15
Cash Income Taxes Paid
0.12 0.80 0.25 0.05 0.10 0.93 0.25 0.25 0.01 0.62 0.27

Annual Balance Sheets for Puma Biotechnology

This table presents Puma Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
240 253 166 259 235 244 227 222 231 213 216
Total Current Assets
224 236 106 203 166 146 140 134 156 148 163
Cash & Equivalents
32 194 82 108 60 85 63 76 85 69 30
Restricted Cash
- - - - 8.85 8.85 8.85 - - 0.00 2.09
Short-Term Investments
184 35 - 57 52 8.10 19 4.87 11 32 68
Accounts Receivable
- - 9.67 21 29 26 33 40 48 32 54
Inventories, net
- - 2.03 2.63 3.17 3.45 7.11 4.53 7.08 8.72 5.52
Prepaid Expenses
7.66 7.00 13 12 13 11 8.98 5.90 4.42 5.87 3.64
Other Current Assets
- - - 1.79 0.48 3.64 0.45 2.43 0.91 0.09 0.26
Plant, Property, & Equipment, net
2.38 5.15 4.47 3.96 3.30 2.48 1.76 1.15 0.86 0.52 0.19
Total Noncurrent Assets
14 11 55 52 65 96 85 87 73 65 53
Noncurrent Note & Lease Receivables
- - - - 19 16 14 11 7.79 4.58 5.37
Goodwill
- - 48 44 40 74 66 71 61 51 41
Noncurrent Deferred & Refundable Income Taxes
- - - - - - - - 0.00 7.08 3.83
Other Noncurrent Operating Assets
9.60 6.85 1.99 7.75 2.00 1.75 1.35 2.07 2.73 0.28 2.83
Total Liabilities & Shareholders' Equity
240 253 166 259 235 244 227 222 231 213 216
Total Liabilities
34 43 112 225 217 250 229 200 177 121 86
Total Current Liabilities
32 37 58 67 91 114 110 77 99 96 81
Short-Term Debt
- - - - 0.00 14 - 0.00 34 45 23
Accounts Payable
18 20 28 21 19 12 11 6.44 6.89 5.51 5.06
Accrued Expenses
15 17 31 46 69 82 93 66 53 37 50
Other Current Liabilities
- - - - 2.62 5.58 5.84 5.51 5.78 8.38 3.64
Total Noncurrent Liabilities
1.39 5.51 54 158 127 136 119 123 78 25 4.71
Other Noncurrent Operating Liabilities
- - - - 32 52 22 25 12 3.38 4.71
Commitments & Contingencies
0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
206 210 53 34 17 -5.95 -2.45 22 53 92 130
Total Preferred & Common Equity
206 210 53 34 17 -5.95 -2.45 22 53 92 130
Total Common Equity
206 210 53 34 17 -5.95 -2.45 22 53 92 130
Common Stock
727 1,006 1,142 1,236 1,295 1,332 1,364 1,388 1,399 1,407 1,414
Retained Earnings
-521 -797 -1,088 -1,202 -1,278 -1,338 -1,367 -1,367 -1,345 -1,315 -1,284
Accumulated Other Comprehensive Income / (Loss)
-0.15 -0.01 - -0.01 0.06 0.00 -0.00 0.00 -0.00 0.01 0.04

Quarterly Balance Sheets for Puma Biotechnology

This table presents Puma Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
204 214 205 221 196 195 203 193 193 203
Total Current Assets
125 143 138 157 133 137 144 142 145 158
Cash & Equivalents
82 77 67 67 63 55 54 36 37 42
Restricted Cash
- - - - - 2.09 2.09 2.09 0.00 0.00
Short-Term Investments
3.23 30 30 29 30 41 41 65 57 67
Accounts Receivable
29 25 28 55 25 26 34 26 34 33
Inventories, net
5.68 7.10 9.05 2.67 8.75 8.59 9.48 8.69 13 11
Prepaid Expenses
3.68 3.92 3.49 2.54 5.32 3.89 3.83 3.41 3.59 4.57
Other Current Assets
1.99 0.26 0.24 0.24 0.10 0.07 0.23 0.20 0.20 0.17
Plant, Property, & Equipment, net
0.91 0.76 0.68 0.60 0.47 0.39 0.31 0.12 0.10 0.08
Total Noncurrent Assets
77 70 67 63 63 58 59 50 48 45
Noncurrent Note & Lease Receivables
8.54 7.02 6.23 5.42 3.72 2.83 6.15 4.57 4.42 4.27
Goodwill
63 58 56 54 49 46 44 39 37 34
Noncurrent Deferred & Refundable Income Taxes
- - - - 7.08 7.08 7.08 3.83 3.83 3.83
Other Noncurrent Operating Assets
2.91 2.82 2.28 2.23 1.62 1.79 1.93 2.96 2.79 2.86
Total Liabilities & Shareholders' Equity
204 214 205 221 196 195 203 193 193 203
Total Liabilities
165 163 156 150 99 90 88 64 54 56
Total Current Liabilities
67 98 104 110 87 79 83 60 50 52
Short-Term Debt
23 45 45 45 45 34 34 11 0.00 0.00
Accounts Payable
5.06 8.96 14 7.51 6.03 5.42 6.39 8.17 3.11 5.06
Accrued Expenses
34 38 39 51 27 32 37 38 45 46
Other Current Liabilities
5.86 6.18 6.46 6.90 8.44 7.88 5.51 1.91 1.59 1.37
Total Noncurrent Liabilities
98 65 52 39 12 11 4.87 4.55 4.37 4.18
Other Noncurrent Operating Liabilities
21 10 8.46 6.49 1.76 0.23 4.87 4.55 4.37 4.18
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
39 51 49 71 97 105 115 128 139 147
Total Preferred & Common Equity
39 51 49 71 97 105 115 128 139 147
Total Common Equity
39 51 49 71 97 105 115 128 139 147
Common Stock
1,396 1,401 1,403 1,405 1,409 1,411 1,412 1,416 1,418 1,420
Retained Earnings
-1,357 -1,350 -1,355 -1,334 -1,312 -1,306 -1,297 -1,288 -1,279 -1,273
Accumulated Other Comprehensive Income / (Loss)
-0.00 -0.03 -0.03 0.03 -0.01 -0.01 0.02 -0.03 -0.05 -0.10

Annual Metrics And Ratios for Puma Biotechnology

This table displays calculated financial ratios and metrics derived from Puma Biotechnology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 806.60% 8.47% -17.32% 12.46% -9.92% 3.34% -2.19% -0.91%
EBITDA Growth
-69.15% -14.01% -6.18% 66.52% 51.34% 23.29% 109.11% 539.44% 113.12% -3.49% 13.64%
EBIT Growth
-68.85% -15.28% -5.60% 64.32% 47.05% 16.35% 82.68% 240.29% 197.25% -4.70% 20.42%
NOPAT Growth
-68.88% -15.11% -5.71% 67.63% 58.75% 22.14% 104.24% -88.50% 29,841.01% 25.17% -16.64%
Net Income Growth
-68.55% -15.35% -5.78% 61.10% 33.44% 20.64% 51.45% 100.01% 1,079,450.00% 40.23% 2.75%
EPS Growth
-57.51% -11.28% 5.31% 61.91% 0.00% 0.00% 52.63% 100.00% 0.00% 37.78% -1.61%
Operating Cash Flow Growth
-100.08% 8.27% -21.72% 86.02% 192.83% -96.55% 2,571.41% -176.64% 270.65% 44.09% 7.41%
Free Cash Flow Firm Growth
-138.46% -2.42% -32.94% 70.84% 108.18% -451.25% 38.16% -182.39% 134.29% 208.69% -6.74%
Invested Capital Growth
44.32% -68.86% 165.77% 31.76% -159.66% -6.44% 102.87% 9,464.64% 51.91% 1.90% -5.12%
Revenue Q/Q Growth
0.00% 0.00% 355.57% 24.55% -18.57% 23.99% 1.12% 4.74% 2.84% -5.38% 7.72%
EBITDA Q/Q Growth
-6.33% -3.98% 3.36% 27.49% 48.57% -311.34% 121.96% -32.43% 69.56% -4.10% 7.49%
EBIT Q/Q Growth
-6.40% -4.07% 3.08% 25.66% 44.75% -159.96% 69.53% -46.05% 116.76% -5.37% 10.42%
NOPAT Q/Q Growth
-6.40% -4.08% 3.08% 32.24% 47.73% -1,321.98% 107.78% -99.47% 36.81% 27.44% -19.21%
Net Income Q/Q Growth
-6.33% -4.13% 2.86% 22.72% 20.50% -6.75% 39.63% -99.98% 480.87% 30.28% -15.87%
EPS Q/Q Growth
-4.63% -1.47% 3.92% 23.33% 0.00% 0.00% 40.00% -100.00% 462.50% 31.91% -18.67%
Operating Cash Flow Q/Q Growth
-10.41% -5.93% 3.01% 63.89% -19.68% -90.31% 0.98% 45.32% 11.44% 15.26% -2.76%
Free Cash Flow Firm Q/Q Growth
-9.24% -7.40% -21.11% 56.54% -60.74% -57.10% 42.42% -17.55% 3.09% 23.71% -7.06%
Invested Capital Q/Q Growth
-95.90% -8.46% 150.07% -40.14% 61.80% 36.89% 103.61% -8.46% 9.22% 11.46% 1.41%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 79.87% 86.21% 86.48% 82.51% 74.84% 75.84% 73.40% 72.06% 74.53%
EBITDA Margin
0.00% 0.00% -1,046.34% -38.64% -17.33% -16.08% 1.30% 9.24% 19.06% 18.81% 21.57%
Operating Margin
0.00% 0.00% -1,056.13% -37.71% -14.34% -13.51% 0.51% 10.40% 13.85% 13.44% 16.33%
EBIT Margin
0.00% 0.00% -1,056.50% -41.58% -20.30% -20.54% -3.16% 4.93% 14.17% 13.81% 16.78%
Profit (Net Income) Margin
0.00% 0.00% -1,054.56% -45.25% -27.77% -26.65% -11.51% 0.00% 9.16% 13.14% 13.62%
Tax Burden Percent
100.00% 100.00% 100.00% 100.02% 100.07% 100.35% 101.12% 0.44% 95.22% 125.63% 86.95%
Interest Burden Percent
99.60% 99.65% 99.82% 108.80% 136.69% 129.32% 359.62% 4.07% 67.89% 75.72% 93.36%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 99.56% 4.78% -25.63% 13.05%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -362.71% -652.38% 0.00% 0.00% 0.57% 68.07% 69.98% 59.31%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -177.42% -429.92% 0.00% 0.00% -0.60% -48.60% 120.16% 61.64%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 103.43% 360.33% 0.00% 0.00% -0.55% -10.53% -28.38% -31.34%
Return on Equity (ROE)
-148.14% -132.75% -221.91% -259.28% -292.05% -1,042.30% 693.72% 0.02% 57.54% 41.60% 27.97%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -1,550.41% -390.12% 0.00% 0.00% -3,341.95% -195.29% 26.86% 68.09% 64.56%
Operating Return on Assets (OROA)
0.00% 0.00% -139.84% -49.16% -22.37% -19.30% -3.40% 5.01% 14.76% 14.34% 17.84%
Return on Assets (ROA)
0.00% 0.00% -139.59% -53.49% -30.60% -25.04% -12.37% 0.00% 9.54% 13.64% 14.48%
Return on Common Equity (ROCE)
-148.14% -132.75% -221.91% -259.28% -292.05% -1,042.30% 693.72% 0.02% 57.54% 41.60% 27.97%
Return on Equity Simple (ROE_SIMPLE)
-116.15% -131.54% -547.74% -331.06% -432.89% 1,008.15% 1,190.76% 0.01% 0.00% 32.87% 0.00%
Net Operating Profit after Tax (NOPAT)
-168 -194 -205 -66 -27 -21 0.90 0.10 31 39 32
NOPAT Margin
0.00% 0.00% -739.29% -26.40% -10.04% -9.45% 0.36% 0.05% 13.19% 16.88% 14.20%
Net Nonoperating Expense Percent (NNEP)
-39.19% -36.30% -64.34% -185.29% -222.46% -208.73% -1,360.63% 1.17% 116.67% -50.18% -2.33%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 0.09% 20.30% 24.44% 21.22%
Cost of Revenue to Revenue
0.00% 0.00% 20.13% 13.79% 13.52% 17.49% 25.16% 24.16% 26.60% 27.94% 25.47%
SG&A Expenses to Revenue
0.00% 0.00% 385.38% 58.24% 52.02% 52.64% 45.94% 39.46% 38.17% 34.78% 31.02%
R&D to Revenue
0.00% 0.00% 750.62% 65.68% 48.80% 43.38% 28.39% 25.98% 21.38% 23.84% 27.18%
Operating Expenses to Revenue
0.00% 0.00% 1,136.01% 123.92% 100.82% 96.01% 74.33% 65.44% 59.55% 58.62% 58.20%
Earnings before Interest and Taxes (EBIT)
-240 -277 -292 -104 -55 -46 -8.01 11 33 32 38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-239 -273 -290 -97 -47 -36 3.30 21 45 43 49
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
12.34 5.39 69.60 22.62 19.52 0.00 0.00 8.93 3.85 1.63 2.30
Price to Tangible Book Value (P/TBV)
12.34 5.39 749.91 0.00 0.00 0.00 0.00 0.00 0.00 3.65 3.37
Price to Revenue (P/Rev)
0.00 0.00 134.00 3.09 1.25 1.81 0.49 0.85 0.87 0.65 1.31
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 96,528.89 9.54 4.94 9.64
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.48% 20.22% 10.38%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 233.23 36.71 0.00 0.00 335.40 5.73 3.77 2.03 4.18
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 132.80 3.04 1.14 1.78 0.50 0.91 0.88 0.49 0.98
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 38.57 9.85 4.62 2.62 4.52
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.49 6.22 3.57 5.81
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 140.77 2,000.82 6.68 2.92 6.87
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 13.90 518.40 6.16 0.00 7.69 2.92 5.33
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 53.34 0.00 0.00 0.00 16.93 3.00 6.31
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.91 4.43 5.44 -16.52 -39.69 4.55 1.86 0.73 0.17
Long-Term Debt to Equity
0.00 0.00 0.91 4.43 5.44 -14.12 -39.69 4.55 1.23 0.24 0.00
Financial Leverage
-1.12 -1.09 -1.03 -0.58 -0.84 -3.22 0.53 0.91 0.22 -0.24 -0.51
Leverage Ratio
1.25 1.18 1.59 4.85 9.54 41.62 -56.07 23.41 6.03 3.05 1.93
Compound Leverage Factor
1.24 1.18 1.59 5.27 13.04 53.82 -201.63 0.95 4.09 2.31 1.80
Debt to Total Capital
0.00% 0.00% 47.63% 81.57% 84.47% 106.44% 102.58% 81.98% 65.09% 42.12% 14.73%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 15.47% 0.00% 0.00% 22.21% 28.48% 14.73%
Long-Term Debt to Total Capital
0.00% 0.00% 47.63% 81.57% 84.47% 90.98% 102.58% 81.98% 42.89% 13.64% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 52.37% 18.43% 15.53% -6.44% -2.58% 18.02% 34.91% 57.88% 85.27%
Debt to EBITDA
0.00 0.00 -0.17 -1.57 -2.01 -2.72 29.46 4.66 2.22 1.55 0.46
Net Debt to EBITDA
0.00 0.00 0.11 0.14 0.63 0.20 0.86 0.69 0.04 -0.83 -1.57
Long-Term Debt to EBITDA
0.00 0.00 -0.17 -1.57 -2.01 -2.32 29.46 4.66 1.46 0.50 0.00
Debt to NOPAT
0.00 0.00 -0.24 -2.29 -3.47 -4.62 107.52 947.01 3.21 1.72 0.69
Net Debt to NOPAT
0.00 0.00 0.16 0.20 1.09 0.34 3.13 141.05 0.05 -0.93 -2.38
Long-Term Debt to NOPAT
0.00 0.00 -0.24 -2.29 -3.47 -3.95 107.52 947.01 2.11 0.56 0.00
Altman Z-Score
39.71 8.70 5.31 -4.15 -5.91 -6.24 -6.96 -6.54 -5.68 -6.03 -4.12
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
6.89 6.31 1.82 3.02 1.83 1.28 1.28 1.73 1.57 1.54 2.00
Quick Ratio
6.65 6.13 1.57 2.77 1.55 1.04 1.05 1.57 1.45 1.38 1.86
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-179 -184 -244 -71 5.83 -20 -13 -36 12 38 35
Operating Cash Flow to CapEx
-13,079.42% -1,945.22% -40,016.24% -3,958.13% 7,312.42% 1,680.43% 0.00% 0.00% 19,292.14% 69,496.43% 58,876.06%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -339.45 -6.49 0.25 -1.46 -0.60 -3.09 0.92 3.04 5.33
Operating Cash Flow to Interest Expense
0.00 0.00 -239.54 -2.19 0.97 0.06 0.99 -1.37 2.03 3.13 6.31
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -240.14 -2.25 0.95 0.05 0.99 -1.37 2.02 3.12 6.30
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.13 1.18 1.10 0.94 1.08 1.02 1.04 1.04 1.06
Accounts Receivable Turnover
0.00 0.00 0.00 16.49 10.96 8.27 8.72 6.26 5.34 5.77 5.33
Inventory Turnover
0.00 0.00 0.00 14.88 12.71 11.89 12.06 9.47 10.80 8.15 8.17
Fixed Asset Turnover
0.00 0.00 5.75 59.53 74.93 77.83 119.50 157.15 235.52 336.45 650.63
Accounts Payable Turnover
0.00 0.00 0.23 1.43 1.85 2.52 5.48 6.26 9.41 10.39 11.01
Days Sales Outstanding (DSO)
0.00 0.00 0.00 22.14 33.29 44.13 41.86 58.32 68.30 63.23 68.46
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 24.53 28.73 30.70 30.26 38.54 33.79 44.78 44.68
Days Payable Outstanding (DPO)
0.00 0.00 1,563.20 255.01 197.63 144.89 66.61 58.35 38.81 35.13 33.15
Cash Conversion Cycle (CCC)
0.00 0.00 -1,563.20 -208.34 -135.61 -70.05 5.51 38.52 63.28 72.88 79.99
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-14 -24 16 21 -12 -13 0.38 36 55 56 53
Invested Capital Turnover
0.00 0.00 -6.75 13.74 64.99 -17.60 -39.52 12.45 5.16 4.15 4.18
Increase / (Decrease) in Invested Capital
11 -9.77 40 5.01 -33 -0.80 14 36 19 1.05 -2.87
Enterprise Value (EV)
2,327 901 3,677 763 311 401 127 208 208 114 223
Market Capitalization
2,543 1,130 3,710 776 341 408 124 193 206 150 300
Book Value per Share
$6.35 $5.70 $1.42 $0.90 $0.45 ($0.15) ($0.06) $0.47 $1.12 $1.88 $2.59
Tangible Book Value per Share
$6.35 $5.70 $0.13 ($0.26) ($0.59) ($2.01) ($1.68) ($1.07) ($0.16) $0.84 $1.77
Total Capital
206 210 102 186 112 92 95 120 153 159 153
Total Debt
0.00 0.00 48 152 95 98 97 98 100 67 23
Total Long-Term Debt
0.00 0.00 48 152 95 84 97 98 66 22 0.00
Net Debt
-216 -229 -33 -14 -30 -7.24 2.83 15 1.63 -36 -77
Capital Expenditures (CapEx)
1.18 7.28 0.43 0.61 0.31 0.05 0.00 0.00 0.14 0.06 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-25 -30 -34 -30 -45 -56 -61 -24 -5.14 -4.09 4.34
Debt-free Net Working Capital (DFNWC)
191 199 48 136 75 46 30 57 91 97 104
Net Working Capital (NWC)
191 199 48 136 75 32 30 57 57 52 81
Net Nonoperating Expense (NNE)
71 82 87 47 48 39 30 0.10 9.49 8.63 1.32
Net Nonoperating Obligations (NNO)
-220 -234 -38 -14 -30 -7.24 2.83 15 1.63 -36 -77
Total Depreciation and Amortization (D&A)
0.96 4.15 2.81 7.38 8.08 10 11 9.84 12 12 11
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% -121.52% -11.77% -16.54% -24.91% -23.91% -10.65% -2.18% -1.77% 1.90%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 173.57% 54.14% 27.72% 20.51% 12.02% 24.91% 38.53% 42.03% 45.52%
Net Working Capital to Revenue
0.00% 0.00% 173.57% 54.14% 27.72% 14.16% 12.02% 24.91% 24.11% 22.37% 35.66%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($7.45) ($8.29) ($7.85) ($2.99) ($1.95) ($1.52) ($29,126.00) $0.00 $0.46 $0.62 $0.62
Adjusted Weighted Average Basic Shares Outstanding
32.49M 36.95M 37.72M 38.50M 39.30M 40.26M 41.33M 44.67M 47.13M 48.65M 50.01M
Adjusted Diluted Earnings per Share
($7.45) ($8.29) ($7.85) ($2.99) ($1.95) ($1.52) $0.00 $0.00 $0.45 $0.62 $0.61
Adjusted Weighted Average Diluted Shares Outstanding
32.49M 36.95M 37.72M 38.50M 39.30M 40.26M 41.33M 44.93M 47.55M 49.10M 50.65M
Adjusted Basic & Diluted Earnings per Share
($7.45) ($8.29) ($7.85) ($2.99) ($1.95) ($1.52) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
32.13M 33.30M 37.17M 37.94M 38.77M 39.58M 40.64M 46.64M 48.21M 49.61M 50.88M
Normalized Net Operating Profit after Tax (NOPAT)
-168 -194 -205 -66 -27 -21 0.90 17 31 22 32
Normalized NOPAT Margin
0.00% 0.00% -739.29% -26.40% -10.04% -9.45% 0.36% 7.28% 13.19% 9.41% 14.20%
Pre Tax Income Margin
0.00% 0.00% -1,054.56% -45.24% -27.75% -26.56% -11.38% 0.20% 9.62% 10.46% 15.67%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -406.24 -9.50 -2.39 -3.29 -0.38 0.97 2.51 2.56 5.79
NOPAT to Interest Expense
0.00 0.00 -284.27 -6.03 -1.18 -1.52 0.04 0.01 2.33 3.12 4.90
EBIT Less CapEx to Interest Expense
0.00 0.00 -406.84 -9.56 -2.40 -3.29 -0.38 0.97 2.50 2.55 5.78
NOPAT Less CapEx to Interest Expense
0.00 0.00 -284.87 -6.09 -1.20 -1.52 0.04 0.01 2.32 3.12 4.89
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13,850.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Puma Biotechnology

This table displays calculated financial ratios and metrics derived from Puma Biotechnology's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
48,207,162.00 48,238,850.00 49,046,723.00 - 49,610,799.00 49,638,093.00 50,370,723.00 - 50,876,487.00 50,899,456.00 51,620,066.00
DEI Adjusted Shares Outstanding
48,207,162.00 48,238,850.00 49,046,723.00 - 49,610,799.00 49,638,093.00 50,370,723.00 - 50,876,487.00 50,899,456.00 51,620,066.00
DEI Earnings Per Adjusted Shares Outstanding
-0.10 -0.09 0.41 - 0.06 0.12 0.18 - -0.07 0.16 0.12
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-17.07% -13.72% 43.53% -18.15% 5.12% 11.37% -32.36% 27.72% -2.59% 7.75% 1.07%
EBITDA Growth
-90.43% -88.73% 119.37% -10.12% 936.14% 1,008.36% -50.96% 20.83% -115.60% 3.07% -37.58%
EBIT Growth
-151.08% -140.64% 158.99% -11.70% 296.69% 448.29% -56.80% 26.52% -185.15% 7.78% -45.37%
NOPAT Growth
-140.74% -133.92% 162.87% 48.70% 325.36% 513.19% -57.92% -36.26% -173.89% 19.54% -44.44%
Net Income Growth
-443.68% -313.03% 250.53% 57.36% 161.77% 229.28% -56.47% -30.39% -226.19% 39.86% -32.65%
EPS Growth
-433.33% -280.00% 241.67% 60.00% 160.00% 233.33% -58.54% -35.00% -216.67% 33.33% -35.29%
Operating Cash Flow Growth
325.50% -68.84% 3.98% 49.28% -67.88% 1,271.18% -12.22% -7.61% 326.80% -88.47% 50.47%
Free Cash Flow Firm Growth
-179.39% 94.41% 959.41% 531.81% 71.28% -153.65% -67.94% -18.59% 253.26% 320.38% 179.29%
Invested Capital Growth
0.00% -26.13% -0.14% 1.90% 38.51% 33.17% 4.29% -5.12% -37.64% -13.27% -27.55%
Revenue Q/Q Growth
-39.36% 7.58% 71.06% -26.65% -22.12% 13.97% 3.89% 38.51% -40.61% 26.08% -2.56%
EBITDA Q/Q Growth
-96.24% 28.45% 2,759.21% -34.90% -56.67% 37.40% 26.52% 60.40% -105.60% 1,007.54% -23.38%
EBIT Q/Q Growth
-114.30% 8.38% 1,208.55% -39.21% -68.14% 62.24% 37.50% 78.05% -121.44% 305.35% -30.30%
NOPAT Q/Q Growth
-111.35% 5.22% 1,527.08% -3.14% -82.80% 73.78% 45.34% 46.70% -119.94% 381.14% -32.44%
Net Income Q/Q Growth
-139.25% 5.94% 548.60% -4.98% -84.59% 96.87% 51.05% 51.94% -127.93% 318.20% -27.27%
EPS Q/Q Growth
-140.00% 10.00% 555.56% -2.44% -85.00% 100.00% 41.67% 52.94% -126.92% 328.57% -31.25%
Operating Cash Flow Q/Q Growth
7.57% -90.87% 974.78% 41.39% -76.86% 289.87% -31.20% 48.82% 6.91% -89.47% 797.72%
Free Cash Flow Firm Q/Q Growth
-834.53% 128.02% 79.79% -8.27% -162.15% 47.66% 207.44% 132.94% 17.00% -24.74% 36.17%
Invested Capital Q/Q Growth
-24.19% -7.42% 30.26% 11.46% 3.05% -10.99% 2.01% 1.41% -32.27% 23.79% -14.79%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
75.49% 77.36% 63.87% 76.44% 77.06% 76.54% 77.65% 69.35% 76.74% 77.92% 72.40%
EBITDA Margin
1.57% 1.88% 31.42% 27.89% 15.52% 18.71% 22.78% 26.38% -2.49% 17.89% 14.07%
Operating Margin
-5.25% -4.63% 27.41% 22.62% 8.66% 12.66% 17.57% 22.67% -8.54% 13.42% 9.58%
EBIT Margin
-5.05% -4.30% 27.84% 23.08% 9.44% 13.44% 17.78% 22.86% -8.25% 13.44% 9.61%
Profit (Net Income) Margin
-11.00% -9.62% 25.23% 32.68% 6.46% 11.17% 16.24% 17.81% -8.37% 14.49% 10.82%
Tax Burden Percent
104.79% 109.11% 98.59% 157.75% 91.03% 94.97% 95.68% 78.55% 109.51% 99.32% 96.50%
Interest Burden Percent
208.11% 205.19% 91.89% 89.77% 75.22% 87.50% 95.41% 99.18% 92.67% 108.57% 116.61%
Effective Tax Rate
0.00% 0.00% 1.41% -57.75% 8.97% 5.03% 4.32% 21.45% 0.00% 0.68% 3.50%
Return on Invested Capital (ROIC)
-39.92% -15.61% 130.65% 147.95% 36.85% 63.50% 69.32% 74.38% -28.94% 64.16% 47.34%
ROIC Less NNEP Spread (ROIC-NNEP)
29.51% -65.40% 162.65% 158.29% 39.54% 64.92% 70.07% 74.38% -27.31% 63.27% 46.32%
Return on Net Nonoperating Assets (RNNOA)
-5.35% -10.00% -13.42% -37.39% -12.95% -26.74% -31.40% -37.81% 15.94% -38.27% -30.31%
Return on Equity (ROE)
-45.27% -25.61% 117.23% 110.56% 23.89% 36.76% 37.92% 36.56% -13.00% 25.89% 17.03%
Cash Return on Invested Capital (CROIC)
-84.26% 66.06% 60.73% 68.09% 56.81% 88.71% 73.86% 64.56% 99.01% 68.50% 80.92%
Operating Return on Assets (OROA)
-5.34% -4.64% 31.97% 23.96% 10.71% 16.00% 17.80% 24.30% -9.64% 16.03% 10.99%
Return on Assets (ROA)
-11.64% -10.40% 28.96% 33.93% 7.33% 13.29% 16.25% 18.93% -9.78% 17.29% 12.37%
Return on Common Equity (ROCE)
-45.27% -25.61% 117.23% 110.56% 23.89% 36.76% 37.92% 36.56% -13.00% 25.89% 17.03%
Return on Equity Simple (ROE_SIMPLE)
30.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.61 -1.53 22 21 3.63 6.30 9.16 13 -2.68 7.53 5.09
NOPAT Margin
-3.68% -3.24% 27.03% 35.69% 7.88% 12.02% 16.81% 17.81% -5.98% 13.33% 9.24%
Net Nonoperating Expense Percent (NNEP)
-69.43% 49.79% -32.00% -10.34% -2.69% -1.42% -0.76% 0.00% -1.63% 0.89% 1.01%
Return On Investment Capital (ROIC_SIMPLE)
-1.07% -1.11% 14.59% 13.25% 2.37% 4.21% 6.15% 8.79% -1.92% 5.44% 3.47%
Cost of Revenue to Revenue
24.51% 22.64% 36.13% 23.56% 22.94% 23.46% 22.35% 30.65% 23.26% 22.08% 27.60%
SG&A Expenses to Revenue
49.70% 53.04% 20.88% 28.14% 38.26% 34.42% 30.87% 24.36% 41.11% 31.06% 29.61%
R&D to Revenue
31.04% 28.95% 15.58% 25.68% 30.13% 29.47% 29.21% 22.32% 44.17% 33.44% 33.21%
Operating Expenses to Revenue
80.74% 81.99% 36.46% 53.81% 68.40% 63.89% 60.08% 46.68% 85.28% 64.50% 62.82%
Earnings before Interest and Taxes (EBIT)
-2.21 -2.02 22 14 4.34 7.05 9.69 17 -3.70 7.59 5.29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
0.69 0.89 25 16 7.14 9.81 12 20 -1.11 10 7.75
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.01 3.24 1.76 1.63 1.51 1.63 2.32 2.30 2.53 2.98 3.50
Price to Tangible Book Value (P/TBV)
0.00 0.00 7.14 3.65 3.03 2.91 3.74 3.37 3.63 4.05 4.56
Price to Revenue (P/Rev)
1.13 0.72 0.51 0.65 0.63 0.72 1.26 1.31 1.43 1.79 2.21
Price to Earnings (P/E)
16.62 18.03 5.38 4.94 3.86 3.51 7.23 9.64 13.33 15.45 21.51
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
6.02% 5.55% 18.58% 20.22% 25.92% 28.46% 13.83% 10.38% 7.50% 6.47% 4.65%
Enterprise Value to Invested Capital (EV/IC)
5.90 3.81 2.07 2.03 1.86 2.27 3.90 4.18 6.45 7.14 10.62
Enterprise Value to Revenue (EV/Rev)
1.09 0.67 0.43 0.49 0.46 0.49 0.97 0.98 1.02 1.38 1.74
Enterprise Value to EBITDA (EV/EBITDA)
6.41 4.69 2.31 2.62 2.16 1.99 4.47 4.52 5.68 7.72 11.02
Enterprise Value to EBIT (EV/EBIT)
9.17 7.42 3.10 3.57 2.80 2.47 5.90 5.81 7.69 10.34 15.28
Enterprise Value to NOPAT (EV/NOPAT)
10.19 9.00 3.42 2.92 2.42 2.22 5.10 6.87 9.42 12.22 18.23
Enterprise Value to Operating Cash Flow (EV/OCF)
6.92 4.42 3.09 2.92 3.44 2.64 4.76 5.33 4.34 7.75 8.78
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 4.91 3.41 3.00 3.80 2.93 5.39 6.31 5.01 9.69 11.03
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.96 1.84 1.10 0.73 0.58 0.43 0.29 0.17 0.09 0.00 0.00
Long-Term Debt to Equity
1.07 0.90 0.46 0.24 0.11 0.10 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.18 0.15 -0.08 -0.24 -0.33 -0.41 -0.45 -0.51 -0.58 -0.60 -0.65
Leverage Ratio
4.20 5.14 3.86 3.05 2.77 2.61 2.27 1.93 1.72 1.59 1.55
Compound Leverage Factor
8.74 10.54 3.55 2.74 2.08 2.28 2.17 1.92 1.60 1.73 1.81
Debt to Total Capital
66.24% 64.74% 52.34% 42.12% 36.57% 29.99% 22.63% 14.73% 8.08% 0.00% 0.00%
Short-Term Debt to Total Capital
30.02% 32.95% 30.39% 28.48% 29.61% 22.73% 22.63% 14.73% 8.08% 0.00% 0.00%
Long-Term Debt to Total Capital
36.22% 31.79% 21.95% 13.64% 6.96% 7.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
33.76% 35.26% 47.66% 57.88% 63.43% 70.01% 77.37% 85.27% 91.92% 100.00% 100.00%
Debt to EBITDA
2.60 2.83 1.73 1.55 1.12 0.76 0.74 0.46 0.28 0.00 0.00
Net Debt to EBITDA
-0.24 -0.31 -0.46 -0.83 -0.79 -0.91 -1.37 -1.57 -2.25 0.00 0.00
Long-Term Debt to EBITDA
1.42 1.39 0.72 0.50 0.21 0.19 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
4.14 5.44 2.56 1.72 1.26 0.85 0.84 0.69 0.46 0.00 0.00
Net Debt to NOPAT
-0.38 -0.60 -0.68 -0.93 -0.89 -1.01 -1.56 -2.38 -3.74 0.00 0.00
Long-Term Debt to NOPAT
2.26 2.67 1.07 0.56 0.24 0.21 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-6.61 -7.42 -6.27 -6.31 -6.93 -6.55 -5.56 -4.45 -4.69 -2.80 -1.46
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.46 1.32 1.42 1.54 1.53 1.73 1.74 2.00 2.38 2.91 3.03
Quick Ratio
1.34 1.20 1.37 1.38 1.37 1.54 1.55 1.86 2.14 2.57 2.72
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-43 12 22 20 -12 -6.52 7.00 16 19 14 20
Operating Cash Flow to CapEx
0.00% 5,135.00% 55,190.00% 97,543.75% 5,921.31% 70,410.00% 37,265.38% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-12.91 3.60 7.05 7.64 -5.72 -3.55 4.70 14.58 26.11 79.79 0.00
Operating Cash Flow to Interest Expense
3.35 0.30 3.56 5.95 1.66 7.67 6.51 12.89 21.09 9.02 0.00
Operating Cash Flow Less CapEx to Interest Expense
3.35 0.30 3.55 5.95 1.63 7.65 6.49 12.92 21.09 9.02 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.06 1.08 1.15 1.04 1.13 1.19 1.00 1.06 1.17 1.19 1.14
Accounts Receivable Turnover
9.22 7.38 5.83 5.77 9.35 8.81 4.81 5.33 8.82 7.71 6.98
Inventory Turnover
8.48 7.07 17.91 8.15 8.10 7.47 8.06 8.17 6.65 5.31 5.84
Fixed Asset Turnover
299.38 264.51 323.04 336.45 378.08 445.81 467.98 650.63 759.79 941.93 1,191.90
Accounts Payable Turnover
6.71 5.54 11.90 10.39 8.57 6.96 7.05 11.01 8.18 13.65 10.70
Days Sales Outstanding (DSO)
39.59 49.46 62.65 63.23 39.02 41.41 75.94 68.46 41.37 47.33 52.27
Days Inventory Outstanding (DIO)
43.05 51.60 20.38 44.78 45.04 48.87 45.29 44.68 54.86 68.72 62.50
Days Payable Outstanding (DPO)
54.36 65.88 30.67 35.13 42.59 52.43 51.80 33.15 44.64 26.75 34.12
Cash Conversion Cycle (CCC)
28.29 35.19 52.36 72.88 41.47 37.85 69.43 79.99 51.60 89.30 80.64
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
42 39 50 56 58 51 53 53 36 45 38
Invested Capital Turnover
10.86 4.82 4.83 4.15 4.67 5.28 4.12 4.18 4.84 4.81 5.12
Increase / (Decrease) in Invested Capital
42 -14 -0.07 1.05 16 13 2.16 -2.87 -22 -6.83 -14
Enterprise Value (EV)
246 147 104 114 108 117 205 223 233 319 404
Market Capitalization
255 157 125 150 147 170 267 300 325 413 513
Book Value per Share
$1.06 $1.01 $1.45 $1.88 $1.96 $2.11 $2.29 $2.59 $2.52 $2.72 $2.84
Tangible Book Value per Share
($0.15) ($0.16) $0.36 $0.84 $0.98 $1.18 $1.42 $1.77 $1.76 $2.00 $2.18
Total Capital
151 138 149 159 153 150 149 153 140 139 147
Total Debt
100 89 78 67 56 45 34 23 11 0.00 0.00
Total Long-Term Debt
55 44 33 22 11 11 0.00 0.00 0.00 0.00 0.00
Net Debt
-9.23 -9.86 -21 -36 -39 -53 -63 -77 -92 -94 -109
Capital Expenditures (CapEx)
0.00 0.02 0.02 0.02 0.06 0.02 0.03 -0.04 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-17 -18 -4.98 -4.09 -1.99 -6.64 -1.91 4.34 -9.83 1.34 -2.91
Debt-free Net Working Capital (DFNWC)
90 79 92 97 91 91 95 104 94 95 106
Net Working Capital (NWC)
45 33 46 52 46 57 61 81 83 95 106
Net Nonoperating Expense (NNE)
3.21 3.00 1.45 1.78 0.65 0.45 0.32 -0.00 1.07 -0.66 -0.87
Net Nonoperating Obligations (NNO)
-9.23 -9.86 -21 -36 -39 -53 -63 -77 -92 -94 -109
Total Depreciation and Amortization (D&A)
2.90 2.91 2.88 2.84 2.80 2.76 2.72 2.66 2.58 2.52 2.45
Debt-free, Cash-free Net Working Capital to Revenue
-7.50% -8.25% -2.04% -1.77% -0.86% -2.79% -0.90% 1.90% -4.33% 0.58% -1.26%
Debt-free Net Working Capital to Revenue
39.79% 35.94% 37.67% 42.03% 39.18% 38.43% 44.61% 45.52% 41.29% 41.19% 45.58%
Net Working Capital to Revenue
19.78% 15.25% 19.06% 22.37% 19.70% 24.14% 28.70% 35.66% 36.32% 41.19% 45.58%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.10) ($0.09) $0.41 $0.40 $0.06 $0.12 $0.18 $0.26 ($0.07) $0.16 $0.12
Adjusted Weighted Average Basic Shares Outstanding
48.19M 48.29M 49.01M 48.65M 49.60M 49.70M 50.34M 50.01M 50.85M 50.94M 51.60M
Adjusted Diluted Earnings per Share
($0.10) ($0.09) $0.41 $0.40 $0.06 $0.12 $0.17 $0.26 ($0.07) $0.16 $0.11
Adjusted Weighted Average Diluted Shares Outstanding
48.19M 48.29M 49.17M 49.10M 49.91M 50.14M 50.93M 50.65M 50.85M 52.60M 53.12M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
48.24M 49.05M 49.09M 49.61M 49.64M 50.37M 50.39M 50.88M 50.90M 51.62M 51.70M
Normalized Net Operating Profit after Tax (NOPAT)
-1.61 -1.53 22 9.36 3.63 6.30 9.16 13 -2.68 7.53 5.09
Normalized NOPAT Margin
-3.68% -3.24% 27.03% 15.84% 7.88% 12.02% 16.81% 17.81% -5.98% 13.33% 9.24%
Pre Tax Income Margin
-10.50% -8.82% 25.59% 20.72% 7.10% 11.76% 16.97% 22.67% -7.65% 14.59% 11.21%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-0.66 -0.60 7.23 5.20 1.99 3.84 6.51 15.41 -5.06 42.19 0.00
NOPAT to Interest Expense
-0.48 -0.45 7.02 8.04 1.67 3.43 6.15 12.01 -3.67 41.85 0.00
EBIT Less CapEx to Interest Expense
-0.66 -0.61 7.23 5.20 1.97 3.82 6.49 15.45 -5.06 42.19 0.00
NOPAT Less CapEx to Interest Expense
-0.48 -0.46 7.02 8.04 1.64 3.42 6.13 12.04 -3.67 41.85 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Puma Biotechnology’s Q2 2026 results showed a meaningful rebound from the first quarter, with stronger revenue, profitability and a substantially improved liability profile. However, operating cash flow weakened sharply as working capital consumed cash, and the company continues to make sizable debt repayments.

Revenue increased to $56.5 million in Q2 2026 from $52.4 million in Q2 2025 and $44.8 million in Q1 2026. Gross profit rose to $44.0 million, producing a gross margin of approximately 77.9%, compared with 76.5% a year earlier. Operating income improved to $7.6 million from $6.6 million in Q2 2025, while net income increased to $8.2 million, or $0.16 per diluted share, from $5.9 million, or $0.12 per diluted share.

The improvement follows a $3.8 million net loss in Q1 2026. Revenue and gross profit were also higher than in the comparable 2025 quarter, although they remain below the much stronger Q3 and Q4 2024 levels. This suggests that Puma’s results continue to fluctuate considerably from quarter to quarter.

The balance sheet has strengthened considerably since 2023 and early 2024. Total liabilities declined to $54.2 million in Q2 2026 from $90.2 million in Q2 2025 and $149.6 million in Q3 2024. Puma reported no short-term debt at June 30, 2026, compared with $45.3 million of short-term debt in Q1 2024. Total equity increased to $138.5 million from $48.5 million in Q2 2024, helped by improved retained earnings and a larger common-stock balance.

Liquidity remains adequate, with $36.5 million of cash and $57.4 million of short-term investments. Total current assets of $145.1 million were nearly three times total current liabilities of $49.8 million. Nevertheless, cash and equivalents have declined substantially from $76.8 million in Q1 2024, making the company increasingly reliant on its investment portfolio and ongoing operating performance.

Operating cash flow was the main weakness in the latest quarter. Puma generated only $1.6 million from operations in Q2 2026, down from $14.1 million in Q2 2025 and $15.4 million in Q1 2026. A $11.0 million use of cash from operating assets and liabilities more than offset net income and noncash adjustments. The company also repaid $11.3 million of debt, resulting in a $1.7 million quarterly decline in cash and equivalents.

  • Revenue increased approximately 8% year over year and 26% sequentially to $56.5 million in Q2 2026.
  • Net income improved to $8.2 million, reversing the prior quarter’s $3.8 million loss and rising nearly 40% from Q2 2025.
  • Gross margin remained strong at approximately 77.9%, up from about 76.5% in the year-ago quarter.
  • Total liabilities have fallen sharply, while reported short-term debt declined to zero by the end of Q2 2026.
  • The current ratio was approximately 2.9, indicating substantial current-asset coverage of current liabilities.
  • Retained losses narrowed to $1.28 billion in Q2 2026 from $1.35 billion in Q2 2024 as the company continued to generate profits over the broader period.
  • Cash and short-term investments totaled approximately $94.9 million, broadly stable from the year-ago period but lower than the company’s cash position in early 2024.
  • Quarterly revenue and earnings remain volatile, with Q2 2026 results improving from Q1 but remaining below the elevated levels reported in Q3 and Q4 2024.
  • Operating cash flow dropped to $1.6 million because changes in receivables, inventories and other operating accounts consumed $11.0 million.
  • Puma continues to repay roughly $11.3 million of debt per quarter, which contributed to negative cash changes in Q2 2026 despite positive operating and investing cash flow.

Overall, Puma’s latest income statement points to improving profitability and its balance sheet is much less leveraged than it was in 2024. Investors should focus on whether the company can sustain revenue growth and convert earnings into operating cash flow, particularly as recurring debt repayments continue to reduce cash balances.

11/17/26 11:44 AM ETAI Generated. May Contain Errors.

Puma Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Puma Biotechnology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Puma Biotechnology's net income appears to be on an upward trend, with a most recent value of $31.11 million in 2025, compared with -$239.28 million in 2015. The previous period was $30.28 million in 2024. See Puma Biotechnology's forecast for analyst expectations on what's next for the company.

Puma Biotechnology's total operating income in 2025 was $37.30 million, based on the following breakdown:
  • Total Gross Profit: $170.21 million
  • Total Operating Expenses: $132.92 million

Over the last 10 years, Puma Biotechnology's total revenue changed from $0.00 in 2015 to $228.37 million in 2025, a change of 22,837,100,000.0%.

In the past 12 quarters, Puma Biotechnology's cash and equivalents has ranged from $36.19 million in Q1 2026 to $81.80 million in Q3 2023, and is currently $41.55 million as of their latest financial filing in Q3 2026.

Puma Biotechnology had total debt of $22.52 million at the end of 2025, a 66.4% decrease from 2024, and none in 2015.

Over the last 10 years, Puma Biotechnology's book value per share changed from 6.35 in 2015 to 2.59 in 2025, a change of -59.3%.



Financial statements for NASDAQ:PBYI last updated on 11/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners